DENVER, Feb. 22, 2012 HepQuant, LLC, a liver diagnostics company focused on delivering a non-invasive alternative to liver function testing, has announced it will begin its first sponsored clinical study of its liver function tests. The prospective, single-center study will establish the performance and reproducibility of HepQuant tests in healthy persons and patients with chronic hepatitis C and fatty liver disease. This study is being conducted at the University of Colorado Hospital’s Clinical Translation Center. Dr. James Burton is serving as Principal Investigator.
“HepQuant tests address a specific unmet medical need: sensitive, specific, accurate, and noninvasive tests for measuring the function of the liver in patients with liver disease,” said Dr. Gregory Everson, HepQuant’s Chief Scientific Officer and Director of Hepatology at the University of Colorado-Denver School of Medicine. “We hope to translate our research findings into valuable clinical tools to enhance the management of patients with liver disease and advance patient care.”
Presently, physicians rely on patient history, medical examination, standard blood tests, live biopsy, and radiologic studies to define liver disease severity, assess progression, and to evaluate the impact of treatments and interventions.
Previous studies utilizing HepQuant technology have focused mainly on patients with chronic Hepatitis C, with additional studies of the cholestatic liver disease, primary sclerosing cholangitis (PSC). “Our goal is to continue to build our portfolio of results and analyses across the broad spectrum of liver disease etiologies, stages of fibrosis, and severity of liver disease,” Dr. Everson added.
HepQuant’s products – HepQuant -STAT™, HepQuant-SHUNT™, and HepQuant-HFR™ – are investigational combination (drug/device) products and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA). They are not currently available for clinical use or commercial sale. Test results should not and cannot be used or relied upon for purposes of clinical decision-making or clinical treatment.
About HepQuant, LLC
HepQuant, LLC, formed in June 2007, is a development stage company pursuing a liver diagnostics product that is innovative in its method for assessing the liver’s portal circulation at all stages of chronic liver disease. Detecting significant hepatic impairment could trigger effective treatment and reduce the risk for future life-threatening complications. More information at: www.hepquant.com.
SOURCE HepQuant, LLCShare This Page